JP2023550654A5 - - Google Patents
Info
- Publication number
- JP2023550654A5 JP2023550654A5 JP2023531565A JP2023531565A JP2023550654A5 JP 2023550654 A5 JP2023550654 A5 JP 2023550654A5 JP 2023531565 A JP2023531565 A JP 2023531565A JP 2023531565 A JP2023531565 A JP 2023531565A JP 2023550654 A5 JP2023550654 A5 JP 2023550654A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- substituted
- compound according
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118291P | 2020-11-25 | 2020-11-25 | |
| US63/118,291 | 2020-11-25 | ||
| PCT/US2021/060844 WO2022115620A1 (en) | 2020-11-25 | 2021-11-24 | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550654A JP2023550654A (ja) | 2023-12-04 |
| JP2023550654A5 true JP2023550654A5 (https=) | 2024-12-03 |
Family
ID=79021144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531565A Pending JP2023550654A (ja) | 2020-11-25 | 2021-11-24 | 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230312522A1 (https=) |
| EP (1) | EP4251618A1 (https=) |
| JP (1) | JP2023550654A (https=) |
| CA (1) | CA3203010A1 (https=) |
| IL (1) | IL303170A (https=) |
| WO (1) | WO2022115620A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309208A (en) | 2021-06-11 | 2024-02-01 | Sage Therapeutics Inc | Neuroactive steroid for the treatment of alzheimer's disease |
| CN115745766B (zh) * | 2022-10-27 | 2024-05-14 | 兰州康鹏威耳化工有限公司 | 一种三氟苯甲醛及三氟苄溴的制备方法 |
| CN117126076A (zh) * | 2023-07-20 | 2023-11-28 | 清源创新实验室 | 一种2,4,6-三氟苯乙腈的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| US8642621B2 (en) * | 2009-09-16 | 2014-02-04 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use |
| AU2011247116B2 (en) * | 2010-04-29 | 2015-12-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1 |
| AP2014007606A0 (en) * | 2011-10-07 | 2014-05-31 | Takeda Pharmaceutical | 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases |
| MX2022003845A (es) * | 2019-09-30 | 2022-06-22 | Actinogen Medical Ltd | Tratamientos cognitivos medicinales. |
-
2021
- 2021-11-24 WO PCT/US2021/060844 patent/WO2022115620A1/en not_active Ceased
- 2021-11-24 JP JP2023531565A patent/JP2023550654A/ja active Pending
- 2021-11-24 CA CA3203010A patent/CA3203010A1/en active Pending
- 2021-11-24 IL IL303170A patent/IL303170A/en unknown
- 2021-11-24 EP EP21830564.7A patent/EP4251618A1/en active Pending
-
2023
- 2023-05-25 US US18/201,885 patent/US20230312522A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7482918B2 (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| AU2023270195B2 (en) | 2,3-dihydroquinazolin compounds as NAV1.8 inhibitors | |
| JP2023550654A5 (https=) | ||
| EP2802577B1 (en) | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | |
| AU2015210833B2 (en) | Dihydropyrrolopyridine inhibitors of ROR-gamma | |
| US6562811B1 (en) | Pyridine derivatives | |
| US11008340B2 (en) | Modulators of ROR-gamma | |
| US9657009B2 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| KR102392684B1 (ko) | Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체 | |
| AU2010212235B2 (en) | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | |
| AU2019211382B2 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| CA2991765C (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| US20120129852A1 (en) | Azaindazoles as kinase inhibitors and use thereof | |
| EP2440204A1 (en) | Nicotinamide compounds useful as kinase modulators | |
| JP2022533436A5 (https=) | ||
| JP2009523748A (ja) | α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用 | |
| US20120053170A1 (en) | Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs | |
| JP7386576B2 (ja) | Ｎ－（１ｈ－イミダゾール－２－イル）ベンズアミド化合物および該化合物を活性成分として含む医薬組成物 | |
| KR102293986B1 (ko) | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2006528147A (ja) | ヒスタミンｈ３受容体リガンドとしての置換ピペリジン | |
| JP2018154554A (ja) | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 | |
| WO2025008732A1 (en) | Novel compounds as modulators of il17 | |
| JP2016000700A (ja) | ２−アミノ置換ピリジン誘導体 | |
| TW202237088A (zh) | 作為抗癌劑的三環化合物 | |
| JP2022522349A (ja) | Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びその使用方法 |